RxDoctor Payments Data

Richard Shewbridge, MD

Endocrinology, Diabetes & Metabolism · Medina, OHNPI 1417935263

Payments from drug & device makers

$902in general payments, 2019–2025

Across 38 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • Dexcom, Inc.$145
  • Amryt Pharma Holdings Ltd$134
  • Lilly USA, LLC$122
  • Ascendis Pharma Endocrinology Inc$107
  • Corcept Therapeutics$64
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$88999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$40,736
Medicare patients
279
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$143,466
OzempicSemaglutide89$120,305
TrulicityDulaglutide76$95,002
JanuviaSitagliptin Phosphate59$84,906
MounjaroTirzepatide60$72,844
Humulin R U-500Insulin Regular, Human15$64,643
Humulin R U-500 KwikpenInsulin Regular, Human20$55,556
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog91$42,880
Fiasp FlextouchInsulin Aspart (Niacinamide)23$36,426
RybelsusSemaglutide13$32,945
Humalog Kwikpen U-100Insulin Lispro67$31,184
Lantus SolostarInsulin Glargine,hum.Rec.Anlog152$25,752
Tresiba Flextouch U-200Insulin Degludec13$23,262
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$23,142
JanumetSitagliptin Phos/Metformin Hcl13$20,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$122$179,657187 claims
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$183$179,466130 claims
Boehringer IngelheimJardiance$13$143,466111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →